The impact of an ARB, with or without hydrochlorothiazide (HCTZ), on glycaemic factors and the risk for developing diabetes in hypertensive patients with the metabolic syndrome have not been fully assessed. This was a 52-week multicentre, prospective, phase-IV, openlabel, cohort study of losartan or losartan/HCTZ in hypertensive patients with metabolic syndrome. All subjects were treated initially with losartan 50 mg day À1 . Those not achieving target blood pressure (BP o140/ 90 mm Hg) were titrated sequentially to losartan 100 mg, losartan 100 mg/HCTZ 12.5 mg, losartan 100 mg/HCTZ 25 mg and finally to losartan 100 mg/HCTZ 25 mg and calcium-channel blocker (CCB), as required. The primary glycaemic outcome measure was change in fasting blood glucose (FBG) and glycosylated haemoglobin A1c (HbA1c) at 52 weeks of treatment. Among the 1897 potentially eligible patients enrolled in the study, 1714 fulfilled the screening criteria. During the 52-week treatment period of the study, FBG and HbA1c did not change significantly. Clinically important and statistically significant changes were observed for both the systolic (SBP) and diastolic BP (DBP) during the study treatment period, with an overall mean decrease of 16.95 mm Hg in SBP (P ¼ 0.001) and 9.84 mm Hg in DBP (P ¼ 0.001). The majority of the patients (77.3%) achieved a target BP of o140/90 mm Hg. In conclusion, losartan, either alone or in combination with HCTZ, is effective in managing hypertension without inducing any change in glycaemic parameters or increasing the risk for developing diabetes in hypertensive patients with the metabolic syndrome.
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Introduction
The metabolic syndrome represents a specific cluster of phenotypes that increase the risk for coronary heart disease and type-2 diabetes mellitus. [1] [2] [3] [4] Owing to the rising prevalence of type-2 diabetes 5, 6 and metabolic syndrome, the development of strategies to prevent the onset of diabetes in moderate or high-risk patient populations is highly valuable. In this perspective, therapeutic interventions that reduce resistance to insulin during the pre-diabetic phase should, in theory, prevent or delay progression to diabetes. The results of clinical trials have shown that lifestyle interventions, including nutrition therapy, weight reduction and exercise, are modestly effective in delaying or preventing the onset of diabetes in patients with impaired glucose tolerance or impaired fasting blood glucose (FBG). [7] [8] [9] For these patients, pharmacological approaches may be required to prevent the onset of diabetes.
Recent large-scale studies have shown that losartan, in addition to lowering blood pressure (BP) in hypertensive patients, provides end-organ protection as well as reduction of long-term mortality and morbidity. 10, 11 The LIFE study, 10 in which 9193 patients aged 55-80 years were followed for an average of 4.8 years, showed a significant 13% relative reduction in cardiovascular morbidity and mortality for losartan compared with atenolol. One of the most notable observations in this patient population was the 25% lower incidence in diabetes onset among the losartan-treated group as compared with that in the atenolol-treated group. This reduction in the new onset of diabetes achieved with losartan is similar to that in studies conducted with other agents intervening at the level of the reninangiotensin system, such as angiotensin-converting enzyme (ACE) inhibitors, suggesting that this class may interfere with insulin resistance. 11 It is noted that the LIFE participants at baseline were hypertensive, with a mean body mass index (BMI) of 28 kg m À2 and mean blood glucose of 6.0 mmol l
À1
, suggesting high prevalence of the metabolic syndrome in this sample. 10 Similarly, a reduced risk for development of type-2 diabetes in patients treated with losartan compared with those on spironolactone was reported by Arase et al. 12 The combination of losartan with a diuretic has been shown to be effective in further reducing the BP and achieving therapeutic targets in patients who do not respond to monotherapy. However, there is some concern regarding glucose intolerance and insulin resistance with thiazide diuretics. [13] [14] [15] [16] Although serum glucose levels remained unchanged in hypertensive patients receiving losartan/HCTZ in a controlled clinical trial, 17 Bakris et al. 18 observed a worsening of FBG and increase in new-onset diabetes in a small-scale prospective study.
The primary objective of this study was to assess the effects of a 52-week losartan-based titration regimen on glucose handling, as measured by FBG and glycosylated haemoglobin A1c (HbA1c) in hypertensive patients with metabolic syndrome on a large scale. The study also assessed in an exploratory manner the effects of losartan on lipid profile, serum uric acid and highly sensitive C-reactive protein (hs-CRP).
Materials and methods

Patients
Patients participating in this study were 18 years of age and older who met the 2005 modified International Diabetes Federation criteria of metabolic syndrome. 19 Accordingly, patients were required to be abdominally obese, defined as a waist circumference of X102 cm in men and X88 cm in women, or ethnic backgroundadjusted BMI X30 kg m
À2
, and with hypertension, defined as BP X140/90 mm Hg and o180/110 mm Hg. Patients were either antihypertensive treatment-naive or treated with no more than two medications, including diuretics, ACE inhibitors or angiotensin-IIreceptor blockers (ARBs). Patients using ARBs, calcium-channel blockers (CCBs) or b-blockers discontinued these medications at the baseline visit and for the duration of the study, with the exception of patients using these medications for indications other than hypertension, including but not limited to stable angina. Patients with controlled hypertension, defined as SBP/DBP o140/90 mm Hg, who were treated with a single antihypertensive agent, but experienced sideeffects warranting discontinuation, were also eligible to participate. As a final eligibility criterion, patients were required to be treated for hyperlipidaemia or fulfil one of the following criteria: FBG X5.6 mmol l À1 and o7.0 mmol l
À1
, or triglycerides (TGs) 41.7 mmol l À1 , or high-density lipoprotein cholesterol o0.9 mmol l À1 (in men) or o1.1 mmol l À1 (in women), as determined by laboratory tests conducted at least 3 months before screening. Patients were excluded from the study if they were diagnosed with type-2 diabetes, defined as FBG levels X7.0 mmol l À1 or a 2hPG in a 75-g OGTT at X11.1 mmol l À1 , or were using any antihyperglycaemic agent. Also excluded were patients who had secondary hypertension, class-3 or 4 heart failure, a myocardial infarction or stroke within the last 6 months, had undergone percutaneous coronary angioplasty or coronary artery bypass within the last 3 months, had clinically significant renal or hepatic dysfunction and/or electrolyte imbalance on the basis of the case history or a recent laboratory test (serum creatinine 4130 mmol l À1 or creatinine clearance o45 ml min
, AST or ALT 42 times above the normal range, serum potassium o3.5 or 45.5 mEq l
), or had a documented history of angio-oedema. The patients underwent screening 2 weeks before enrolment and were assessed at baseline (week 0) with follow-up assessments at 4, 8, 12, 32 and 52 weeks after treatment initiation. During the screening visit, patients were assessed for eligibility and underwent a review of medical history, concomitant medication use and a physical examination with anthropometric measurements. An average of three sitting BP measurements over a 5-min period was obtained according to the investigator's usual practice (standard mercury sphygmomanometer or an electronic BP monitor) using the same arm and device at every visit. Furthermore, blood was drawn for FBG, glycosylated Hb (HbA1c) determination, assessment of safety parameters, lipid profile (total cholesterol, low-density lipoprotein cholesterol (LDL-C), highdensity lipoprotein cholesterol and TGs)) and uric acid measurement at local laboratories. hs-CRP was assessed in a subset of patients. All hs-CRP measurements were conducted at a central laboratory (LifeLabs, Toronto, Ontario, Canada). At the baseline visit, the Framingham equation was used to estimate the 10-year risk for cardiovascular disease. At this point, patients were switched from any previous antihypertensive medication to treatment with losartan 50 mg. Physical examination, BP measurements, review of concomitant medications, compliance monitoring and adverse-event reporting were conducted at all follow-up visits. Follow-up measurements of FBG, HbA1c, lipid profile, uric acid and hs-CRP were conducted at 52 weeks. For patients titrated to losartan 100 mg/HCTZ 25 mg at week 12, an optional visit at week 16 was permitted to assess whether addition of a CCB is required to reach BP goals. Written informed consent was obtained from each subject before entry into the study. The study protocol was approved by a central independent ethics review committee (IRB Services, Aurora, Ontario, Canada).
Study design
Treatment
All patients were treated with an initial dose of losartan 50 mg once daily (losartan 50 mg). If target BP, defined as SBP/DBP p140/90 mm Hg, was not achieved at any of the follow-up visits, the patients were to be titrated sequentially as required, to losartan 100 mg (losartan 100 mg), losartan 100 mg with 12.5 mg hydrochlorothiazide (losartan/HCTZ 100 mg/12.5 mg) or losartan 100 mg with 25 mg HCTZ, (losartan/HCTZ 100 mg/25 mg). For patients not achieving target BP with losartan/HCTZ 100 mg/ 25 mg after 12 weeks of treatment, addition of a CCB was allowed (losartan/HCTZ/CCB).
Outcome measures
The primary outcome measure of the study was a change in FBG and HbA1c between baseline and 52 weeks of treatment. For the change in FBG and HbA1c, the tolerance level for no change was set to p0.5mmol l À1 and p0.5%, respectively. This was based on values for changes in the parameters that are clinically relevant, thus avoiding statistical significance in the absence of clinical relevance. The incidence of new-onset diabetes was defined as FBG X7.0 mmol l À1 during the 52-week follow-up period of the study.
The hypertension effectiveness outcome measures of the study were change in systolic (SBP) and diastolic BP (DBP) at 4, 8, 12, 32 and 52 weeks of treatment. The rate of achieving sustained target BP, defined as SBP/DBP p140/90 mm Hg, during the 52-week treatment period and the proportion of patients with target BP at the 52-week visit were also assessed as effectiveness outcome measures. For the change in SBP and DBP, the tolerance levels for no change were set at ±5.0 and ±3.0 mm Hg, respectively. These levels were again determined in accordance with changes that are considered to be clinically relevant. The changes in TG, LDL-C and high-density lipoprotein cholesterol during the treatment period, as well as the change from baseline to week 52 in uric acid and hs-CRP levels, were included as exploratory outcome measures.
Safety assessments
Safety assessments were based on the incidence of treatment-emergent adverse events, as well as clinically important changes observed during physical examinations and routine laboratory tests. All adverse events were coded by Preferred Term according to the version 12.0 MedDRA Dictionary of terms and were assessed for causal relationship to the study drugs by the treating physician.
Compliance assessment
Compliance with study treatment was assessed by the study medication returned at each visit. A patient was considered to have been compliant with treatment if 80% or more of the study medication was used.
Statistical methods
The intent-to-treat (ITT) approach was used for data analysis. All patients who received at least one dose of the study treatment and had at least one follow-up assessment, were included in the analysis. Sample size calculations were based on change in FBG. The null hypothesis tested was that there would be no change in FBG (H 0 : d ¼ 0) with a tolerance of 0.5 mmol l
À1
. For 80% power and 5% significance while accounting for multiplicity related to subgroup analysis, a total of 2500 patients were required.
Descriptive statistics were reported for patient demographics, baseline characteristics and all study outcome variables at each visit. Patients were stratified according to their baseline BP values as grade-I for SBP p154.9 mm Hg and DBP p99.9 mm Hg, grade-II for SBP X155.0 mm Hg but p179.9 mm Hg or DBP X100.0 mm Hg but p109.9 mm Hg, and grade-3 for SBP X180 mm Hg or DBP X110 mm Hg.
The differences between the tolerance levels for FBG and HbA1c, and their observed mean change at 52 weeks of treatment, were assessed using a one-tailed Student's t-test for paired observations.
Similarly, one-tailed Student's t-test for paired observations was used to assess the statistical significance of the difference between the observed changes from baseline and the tolerance levels for SBP and DBP at each visit. General Linear Model analysis with repeated measures was used to assess the rate of change in SBP and DBP during the 52-week treatment course of the study.
The proportion of patients achieving target the BP of o140/90 mm Hg at 52 weeks of treatment was calculated as the number of patients with the end point over the total number of patients in the ITT population and over the total number of patients completing the study. The mean absolute and percent changes in TG, LDL-C, high-density lipoprotein cholesterol, uric acid and hs-CRP levels between baseline and 52 weeks were assessed descriptively for statistical significance using Student's t-test for paired observations. All analyses were conducted for the sample as a whole and for subgroups defined according to the Losartan with or without HCTZ for hypertensive patients with metabolic syndrome N Racine et al baseline hypertension grade, as well as the final treatment. Between-group differences for continuous variables were assessed for statistical significance with analysis of variance with multiple contrasts and corrected for multiplicity with Tukey's Least Significant Difference. The w 2 -statistic was used to compare the patient subgroups with respect to categorical variables.
Results
Patient disposition and demographics
Among the 2056 subjects screened for the study, 1897 were enrolled and 1738 fulfilled the study eligibility requirements. Of the 1738 eligible patients who were enrolled into the study, 1714 returned for at least one follow-up evaluation and were included in the ITT population. The 24 patients who did not return for any follow-up evaluation did not take any study drug. A total of 1583 (92.4%) completed the 32-week assessment and 1511 (88.2%) completed the 52-week follow-up of the study. Reasons for study discontinuation were lost to follow-up for 120, non-serious adverse event for 40, withdrawal of consent for 20, protocol violation for 9, serious adverse event for 7 and lack of compliance for another 7 patients. Despite the lower than calculated sample size, the power of the study to detect the changes in FBG and HbA1c of 0.5 mmol l À1 and 0.5%, respectively, at 0.01 significance was more than 90%.
Of the 1714 patients in the ITT population, there were 1485 (86.6% with grade-I hypertension, 222 (13.0%) with grade-II and 7 (0.4%) with grade-III). In the subsequent analyses, the patients with grade-II and III hypertension were combined. The mean age of the whole study cohort was 54.9 years; 57.2% were males while the vast majority were Caucasian (84.7%). The majority of the patients were in the low CAD Risk group as assessed by the Framingham model. The most frequently reported comorbidity was dyslipidaemia (57.7%) while 15.3% were current smokers.
The majority (62.0%) of the patients were treatment-naïve at study entry. For those who had been treated with antihypertensive before the study, distribution of prior treatment was ACE inhibitors for 13.0%, ARB for 13.5% and diuretics for 9.5%, while 6.5 and 6.9% had been treated with b-blockers and CCBs, respectively. When compared with patients with grade-II or III hypertension, a significantly higher proportion of patients with grade-I hypertension had received previous treatment for hypertension. Concomitant treatment with a statin was reported by 27.7% of the patients, at baseline. Patients with grade-I hypertension were more likely to be treated with a statin when compared with those with grade-II or III hypertension. The most frequently used statin was atorvastatin.
The final treatment to target BP during the study was losartan 50 mg (36.6%), losartan 100 mg (25.9%), losartan/HCTZ 100 mg/12.5 mg (17.3%), losartan/ HCTZ 100 mg/25 mg (17.1%) and losartan/HCTZ 100 mg/25 mg with a CCB (3.2%; Table 1 ). The most commonly used CCBs were amlodipine, nifedipine and diltiazem (51.1, 37.2 and 9.3% of CCB-treated patients, respectively). As expected, patients with grade-I hypertension required significantly less aggressive treatment when compared with patients with grade-II or III hypertension (Po0.001). Table 2 summarizes the baseline values and change in mean FBG and HbA1c for the study sample as a whole and for patient subgroups stratified according to the hypertension grade. For the total study sample and the subgroups with grade-I and grade-II or III hypertension, the mean change in FBG and HbA1c at 52 weeks was not clinically or statistically significantly different from the tolerance levels of 0.5 mmol l À1 and 0.5%, respectively. The incidence of new-onset diabetes during the 52-week follow-up of the study was 2.2% (n ¼ 37). This incidence was 2.4% for patients with grade-I hypertension and 1.5% for those with grade-II or III hypertension (P ¼ 0.16). Table 3 summarizes the baseline values and changes in mean FBG and HbA1c for the study sample as a whole and by the final treatment regimen used. For patients in the losartan 50-mg and losartan 100-mg groups, there was a nonsignificant decrease in FBG at 52 weeks of treatment, whereas for patients in the losartan/HCTZ 100-mg/ 12.5-mg, losartan/HCTZ 100-mg/25-mg and losartan/HCTZ/CCB groups there was an increase in FBG that was not significantly different from the tolerance level of 0.5 mmol l À1 . Similarly, the increase in HbA1c between the baseline and 52-week assessments was not clinically or statistically significantly different from 0.5%, for any subgroup of patients defined according to the final treatment regimen used. The mean (s.d.) change in FBG at 52 weeks for patients treated with HCTZ was 0.044 mmol l À1 (0.78), compared with 0.004 (0.70) for those not receiving HCTZ. This difference was not statistically significant (P ¼ 0.098). Similarly, non-significant (P ¼ 0.799) changes were observed in HBA1c for patients treated with HCTZ and without HCTZ, respectively (0.048 (0.09) versus 0.031 (0.56)).
FBG and HbA1c
Change in BP
The mean SBP and DBP during the study are summarized in Figures 1 and 2 . The change from baseline in SBP and DBP was clinically and statistically significant for the total study sample, and for patients with grade-I or grade-II/III hypertension. Repeated-measure linear regression analysis showed that for the total study sample, the rate of change in SBP and DBP was À0.245 mm Hg per week (P ¼ 0.001) and À0.143 mm Hg per week (P ¼ 0.001), respectively. For patients with grade-I hypertension, the rate of change in SBP and DBP was À0.195 mm Hg per week (P ¼ 0.001) and À0.120 mmÀHg per week (P ¼ 0.001), respectively, compared with À0.361 mmHg per week (P ¼ 0.001) and À0.195 mm Hg per week (P ¼ 0.001), respectively, for patients with grade-II or III hypertension. The differences in the rate of change of SBP and DBP between the two patient subgroups were statistically significant (P ¼ 0.001), indicating that patients with grade-II or III hypertension experienced a higher rate of SBP and DBP reduction when compared with patients with grade-I hypertension.
BP control
At the end of the 52-week follow-up, the rate of BP control (SBP/DBP o140/90 mm Hg) was 70.0% for the ITT-based analysis. According to the ITT analysis, the 227 patients who discontinued the Losartan with or without HCTZ for hypertensive patients with metabolic syndrome N Racine et al study before the week 52 visit were considered not to have achieved target BP. In the per protocol analysis, which was based only on patients who completed the 52 weeks of follow-up, the rate of BP control was 79.4%. Patients with grade-I hypertension had significantly higher rates of BP control when compared with patients with grade-II or III hypertension (Po0.001).
Exploratory outcomes
The results summarized in Table 3 show that for the study sample as a whole and for patients with grade-I or grade-II/III hypertension, statistically significant reductions between baseline and 52 weeks of treatment were observed for waist circumference (mean (s. 
Safety assessment
There were no serious adverse events attributed to the study drug by the treating physicians. A total of 95 non-serious adverse events attributed causally to the study drug were reported by 77 (4.5%) of the patients. Of these, the most frequently reported was dizziness (1.2%), followed by fatigue, headache and cough, which were reported by 0.4% of the patients in the study.
Compliance
The majority of patients (86.5%) reported taking 80% or more of the study medication.
Discussion
Previous studies suggest that certain antihypertensive agents may have differential effects on glycaemic control. In a review of the published literature on the effect of major antihypertensive classes on glycaemic control parameters, Padwal et al. 20 reported a neutral or beneficial effect of ACE inhibitors, ARBs and CCBs, whereas a negative Abbreviations: CI, confidence interval; FBG, fasting blood glucose (mmol l À1 ); HbA1c, glycosylated haemoglobin (%). Data for FBG were missing for one patient at baseline, for 237 patients at week 52. Data for HbA1c were missing for119 patients at baseline, for 192 patients at week 52. P-value (between-group): Based on Student's t-test for independent samples. Abbreviations: BMI, body mass index; CI, confidence interval; FBG, fasting blood glucose (mmol l À1 ); HbA1c, glycosylated haemoglobin (%); HCTZ, hydrochlorothiazide; HDL-C, high-density lipoprotein cholesterol; hs-CRP, highly sensitive C-reactive protein; LDL-C, low-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride. Data for FBG were missing for one patient at baseline, for 237 patients at week 52. Data for HbA1c were missing for119 patients at baseline, for 192 patients at week 52. *P-values for mean change were all non-significant (PX0.05) based on Students t-test for paired observations, with a tolerance of 0.5 mmol l À1 for FBG and 0.5% for HbA1c. P-value (within-group): Based on student's t-test for paired observations. P-value (between-group): Based on student's t-test for independent samples. effect was observed for b-blockers and thiazide diuretics.
The results of this study have shown that a losartan-based progressive titration protocol, with or without addition of HCTZ, was effective in managing BP, while having no effect on glycaemic parameters, in hypertensive patients with the metabolic syndrome. Furthermore, a modest beneficial effect on some metabolic syndrome parameters, namely waist circumference, BMI, total cholesterol and uric acid, was observed. Although patient populations may differ, the incidence of new-onset diabetes of 2.2% in this study was similar to the rates reported in the literature, which range between 0.5 and 8.1% for hypertensive patients treated with ACE inhibitors or ARBs, as well as to the rates reported for patients treated with a thiazide (2.3%) or b-blocker (range 2.6-8%). 20 In addition, our results of neutral effect on glycaemic parameters are in agreement with those reported from major hypertension trials such as LIFE and VALUE, which reported decreased risk for developing diabetes for patients treated with ARBs. 10, 21 Notably, given that patients in this study had the metabolic syndrome, they were at increased risk of developing diabetes and many required a combination of losartan and HCTZ to achieve BP control (30.1%). As such, a long-term neutral effect of combination therapy on glycaemic control is a desirable outcome. Although thiazide diuretics have been associated previously with increased risk of diabetes when used for patients with hypertension, in our study, approximately 40% of the patients were treated with a thiazide diuretic and did not experience increase in the glycaemic parameters, suggesting a neutralizing action of losartan on the adverse metabolic effect of thiazide diuretics under these conditions. This is in contrast with a recent study reporting worsening of FBG in patients with the metabolic syndrome who received losartan/HCTZ. 18 However, this may reflect inherent differences in the two patient populations such as baseline glycaemic control, which was better in this study.
The majority of the patients in this study achieved their target BP and sustained control of their BP for the duration of the study. The lower BP control rate observed for patients with grade-II or III hypertension is likely due to the higher baseline BP values observed for this group and the fact that these patients may have more resilient disease. The latter assumption is further supported by the fact that these patients required more aggressive treatment, with titration to higher losartan doses to achieve BP control. The results of this study are in general agreement with those published in the literature showing the clinical effectiveness of losartan in the management of hypertension. 10, 11, 22 The losartan-based regimen also had a small but positive impact on many of the exploratory outcome measures. Waist circumference, BMI, total cholesterol and uric acid were decreased in all patient groups. A decrease in LDL-C and TG was also observed in patients with more severe hypertension. These results may be due to a direct effect of the losartan-based regimen or the fact that by participating in the study, patients and physicians were better able to monitor and control the metabolic parameters. Whether or not losartan provides additional cardiovascular benefits through these parameters, will require further research. In addition, approximately 30% of the patients participating in this study were treated by a statin, which may explain the observed improvement in these parameters.
With regard to BP, the effect of statins has been controversial. 23, 24 In this study, the mean reduction in SBP at 52 weeks was À15.6 mm Hg for patients treated with a statin/losartan-based regimen, compared with À17.5 mm Hg for patients treated with a non-statin-containing, losartan-based regimen, while the mean changes in DBP at 52 weeks for these two patient groups were À8.9 and À10.2 mm Hg, respectively. Altogether, these results suggest that statins do not exert a synergistic effect on BP reduction with losartan, in this group of patients. However, since the effect of statins on BP depends on the grade of hypertension, their preparation and their dosage, a possible role in specific hypertension groups or at different preparations/doses, cannot be excluded at this point.
One potential limitation of this study is the lack of a control cohort. However, the aim of the study was to assess the changes in glucose control parameters Losartan with or without HCTZ for hypertensive patients with metabolic syndrome N Racine et al in hypertensive patients treated with losartan who also have the metabolic syndrome and are therefore at high risk for diabetes. In addition, the study aimed at confirming, in a real-life setting, the results from clinical trials suggesting that losartan does not interfere with the glucose control parameters in patients who are at high risk of developing diabetes and particularly those who are on treatment with a thiazide. The strengths of this study include the emulation of the real-life setting and the use of a titration approach in the management of hypertension that is relevant to clinical practice. Postmarketing observational studies emulating the real-life setting are useful to confirm that the efficacy results observed in controlled clinical trials can be generalized to effectiveness in routine care. In addition, tolerability and safety must be assessed in less controlled real-life settings. The results of this study have important implications for the management of patients with hypertension and support the use of losartan-based titration regimens that include combination therapy with HCTZ, given that this treatment approach will not only be effective in managing hypertension, but could also provide additional benefits in glycaemic control and prevention of diabetes.
Conclusion
The results of this prospective cohort study have shown that a stepwise titration regimen of losartan either alone or in combination with HCTZ does not cause any statistically or clinically significant changes in glycaemic control parameters while being effective in reducing BP and achieving sustained BP control in hypertensive patients with the metabolic syndrome.
